PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to compare the sensitivity of PSMA PET/MRI and standard MRI in detecting focal therapy failure in the prostate one year after High-Intensity Focused Ultrasound (HIFU) treatment. Specifically, the study aims to evaluate whether PSMA PET/MRI offers a higher sensitivity than MRI alone for identifying recurrence or failure in patients undergoing focal therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 40-95 lat z potwierdzonym rakiem prostaty na biopsji
- •Rak o średnim lub wyższym stopniu zaawansowania (wynik Gleansona 7 lub wyżej)
- •Zmiana widoczna w jednym miejscu na MRI
- •Pacjenci leczeni ultrasonografią wysokoenergetyczną
- •Poziom PSA poniżej 20 ng/mL
- •Brak przerzutów potwierdzonych w badaniu PET/CT
- •Gotowość do regularnych badań kontrolnych i pobrań próbek
✗ Disqualifies
- •Obecność przerzutów raka potwierdzonych w badaniu PET/CT
- •Alergia na środek kontrastowy POSLUMA lub gadolin
- •Niemożliwość tolerowania MRI z powodu klaustrofobii lub problemów z postawą ciała
Simplified criteria — AI translation
Trial details
- Minimum age
- 40 Years
- Maximum age
- 95 Years
- Last updated (source)
- August 27, 2026
- Sex
- Male only
Locations (1)
NYU Langone Health
New York, United States
Trial contact
Majlinda Tafa
Wei Phin Tan, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.